

GUIDANCE¹

BUSPIRONE HYDROCHLORIDE TABLETS

IN VIVO BIOEQUIVALENCE

AND *IN VITRO* DISSOLUTION TESTING

I. INTRODUCTION

A. Clinical Usage/Pharmacology

Buspirone hydrochloride is an antianxiety agent (1,2). Clinically it is effective in the management of anxiety disorders or short-term relief of symptoms of anxiety. Buspirone has no anticonvulsant or muscle relaxant activity and has little sedative effect. It does not substantially affect psychomotor function (3,4). There is no evidence that the drug causes either physical or psychological dependence (5). The mechanism of action of buspirone is not known. Some *in vitro* preclinical studies indicate that buspirone has high affinity for serotonin (5-HT_{1A}) receptors, and moderate affinity for brain D₂ receptors (5-9).


as For the management of anxiety disorders, the usual initial adult dosage of buspirone is 10-15 mg daily, usually in 2 or 3 divided doses. Dosage is increased necessary in increments of 5 mg daily to achieve an optimal therapeutic response. The maximum daily dose should not exceed 60 mg per day (5).

¹ This statement, prepared by the Division of Bioequivalence in the Office of Generic Drugs, is an informal communication under 21 CFR 10.90(b)(9) that represents the best judgment of the Division at this time. This statement does not necessarily represent the formal position of the Center for Drug Evaluation and Research, Food and Drug Administration, and does not bind or otherwise obligate the Center for Drug Evaluation and Research, Food and Drug Administration, to the views expressed. For further information about this guidance, contact the Division of Bioequivalence, Office of Generic Drugs, 7500 Standish Place, Metro Park North, Rockville, MD 20855 (Phone: 301-594-0290; Fax: 301-594-0183).

Buspirone is currently marketed by Mead Johnson Pharmaceuticals, a subsidiary of Bristol-Myers Squibb Company, under the trade name Buspar[®] in scored oral tablets of 5 and 10 mg.

B. Chemistry

Buspirone Hydrochloride is a white crystalline powder, soluble in water, with a molecular weight of 422. The chemical structure of buspirone is shown below:



C. Pharmacokinetics

Buspirone is rapidly and almost completely absorbed from the GI tract. The drug undergoes extensive first pass metabolism, with about 4 % of a dose reaching the systemic circulation unchanged following oral administration (10,11). Following oral administration of a single dose of 20 mg in healthy volunteers, peak plasma buspirone concentrations of 1 to 6 ng/mL have been observed to occur within 40 to 90 minutes (5,12). Plasma concentrations of unchanged buspirone are low and exhibit substantial interindividual variation with oral administration of the drug (13). Approximately 95 % of buspirone is bound to plasma proteins (14).

Buspirone is rapidly metabolized by oxidation to produce several hydroxylated derivatives and a pharmacologically active metabolite, 1-pyrimidinylpiperazine (10,15). Because of rapid metabolism, less than 1% of the parent drug is excreted unchanged in the urine (10). The pharmacologically active metabolite has about 20-25% of anxiolytic

activity of buspirone. In humans, blood concentrations of the active metabolite (1-PP) remain low even after chronic administration of buspirone. The contribution of 1-PP to the pharmacologic and/or toxic effect thus remains to be fully elucidated.

The average elimination half-life of unchanged buspirone after single doses of 10 to 40 mg is reported to be 2-3 hours (5). Buspirone exhibits linear kinetics following administration of doses (10-40 mg) in the therapeutic range (16). Although food increases the bioavailability of buspirone by decreasing first pass metabolism, the total amount of drug (changed and unchanged) in plasma is not affected (17,18).

II. IN VIVO BIOEQUIVALENCE STUDIES²

A. Product Information

1. FDA Designated Reference Product: BuSpar[®] (Mead Johnson) 10 mg tablets.
2. Batch size: The test batch or lot must be manufactured under production conditions and must be of a size at least 10% that of the largest lot planned for full production or a minimum of 100,000 units, whichever is larger.
3. Potency: The assayed potency of the reference product should not differ from that of the test product by more than 5%.

B. Types of Studies Required

1. A single-dose, randomized, fasting, two-treatment crossover study under fasting conditions comparing equal doses of the test and reference products.
2. A single-dose, randomized, three-treatment, three-period, six-sequence, crossover, limited food effects study comparing equal doses of the test

² The sponsoring firm is advised that an Investigational New Drug Application (IND) filing may be required if dosing levels exceed those recommended in the official labeling. Please refer to 21 CFR 312.2, 320.31(b)(1) and also Office of Generic Drugs Policy and Procedure Guide #36-92, Submission of an "Investigational New Drug Application" to the Office of Generic Drugs, issued October 13, 1992.

and reference products when administered immediately following a standard breakfast.

C. Recommended Protocol for Conducting a Single Dose Bioequivalence Study under Fasting Conditions

Objective: To compare the rate and extent of absorption of a generic formulation with that of a reference formulation when given in equal doses.

Design: A single-dose, randomized, two-period, two-treatment, two-sequence crossover study using sufficient number of subjects to ensure adequate statistical results, and with one week washout period between Phases I and II, or a single-dose, randomized, fasting, two-treatment, four-period, four-sequence replicate design crossover study in fasted subjects with one week washout period between phases of dosing. Equal numbers of subjects should be randomly assigned to the dosing sequences. Before the study begins, the proposed protocols should be approved by an institutional review board.

Facilities: The clinical and analytical laboratories used for the study should be identified along with the names, titles and curriculum vitae of the medical and scientific/analytical directors.

Subjects: The sponsor should enroll a number of subjects sufficient to ensure adequate statistical results. Subjects should be healthy male volunteers, 18 to 50 years in age, and within 10% of ideal body weight for height and build (Metropolitan Life Insurance Company Statistical Bulletin, 1983). Subjects should be selected on the basis of acceptable medical history, physical examination, and clinical laboratory test results. Subjects with any current or past medical condition which might significantly affect their pharmacokinetic or pharmacodynamic response to the administered drug should be excluded from the study. Written, informed consent must be obtained from all study participants before they are accepted into the studies.

Procedures: Following an overnight fast of at least 10 hours, subjects should be administered a single dose (4x10 mg) of the test or reference product with 240 ml of water.

Restrictions: Study volunteers should observe the following restrictions:

1. Water may be allowed except for one hour before and after drug administration when no liquid should be permitted other than that needed for drug dosing.
2. Subjects should fast for at least four hours after administration of the test or reference treatment. All meals should be standardized during the study.
3. No alcohol or xanthine-containing foods or beverages should be consumed for 48 hours prior to dosing and until after the last blood sample is collected.
4. Subjects should take no prescription medications beginning two weeks and no OTC medications beginning one week before drug administration and until after the study is completed.

Blood Sampling: Venous blood samples should be collected pre-dose (0 hours) and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 7.0, 8.0, 12, and 24 hours post-dose. Plasma should be separated promptly and immediately frozen until assayed. Following a washout period of at least one week, subjects should begin the second phase of the study.

Analytical Methods: Buspirone and its active metabolite, 1-pyrimidinylpiperazine (1-PP), should be assayed using a suitable method fully validated with respect to adequate sensitivity, specificity, linearity, recovery, and accuracy and precision (both within and between days). Stability of the samples under frozen conditions, at room temperature, and during freeze-thaw cycles, if appropriate, should be determined. Chromatograms of the analysis of the unknown samples, including all associated standard curve and Q.C. chromatograms, should be submitted for one-fifth of the subjects, chosen at random. The sponsor should justify the rejection of any analytical data and provide a rationale for selection of the reported values.

Statistical Analysis of Pharmacokinetic Data (Plasma):
See Division of Bioequivalence Guidance, "Statistical Procedures for Bioequivalence Studies Using a Standard Two-Treatment Crossover Design or Replicated Treatment Designs."

Clinical Report and Adverse Reactions: Subject medical histories, physical examination reports, and all incidents of possible adverse reactions to the study formulations should be reported.

D. Limited Food Effects Study

A limited food effects study should be performed in the same manner as the single-dose fasted study, with the following exceptions:

Procedures: Equal numbers of subjects should be assigned to each of the six dosing sequences possible in a three-treatment, three-period study design. Each subject will receive the following treatments:

Treatment 1: Generic Product, Buspirone HCl (4x10 mg tablets) administered after a standard breakfast ³.

Treatment 2: Reference (BuSpar[®]) Product, (4x10 mg tablets) administered after a standard breakfast.

Treatment 3: Generic Product, (4x10 mg tablets) administered under fasting conditions.

Following a ten hour fast, subjects receiving treatments 1 and 2 should be served a standard breakfast. The subjects should have thirty minutes to

³ Thirty minutes before drug administration, each subject should consume a standardized, high fat content meal consisting of:

One buttered English Muffin
One fried egg
One slice of American cheese
One slice of Canadian bacon
One serving of hash brown potatoes
Eight fluid oz. (240 mL) of whole milk
Six fluid oz. (180 mL) of orange juice

finish the entire breakfast, then be immediately dosed with 4x10 mg tablets of the test or reference product with 240 ml of water. Subjects receiving Treatment 3 should be dosed with 4x10 mg tablets of the test product with 240 ml of water only. The same lots of the test and reference products used in the study under fasting conditions should be used in the food study. No other food should be allowed for at least 4 hours post-dose. Water may be allowed after the first hour. Subjects should be served scheduled standardized meals throughout the study.

Statistical Analysis: In general, a comparable food effect will be assumed provided the AUC_{0-T} , $AUC_{0-\infty}$, and C_{max} mean values for the test product differ no more than 20% from the respective mean values obtained for the reference product in this study.

Retention of Samples: The laboratory conducting the bioequivalence tests should retain an appropriately identified reserve sample of the test product and the reference standard used to perform the *in vivo* bioequivalence study for approval of the application. Each reserve sample should consist of at least 200 dosage units. For more information please refer to CFR 21, 320.32.

III. IN VITRO TESTING REQUIREMENTS

A. Dissolution Testing

Conduct dissolution testing on 12 dosage units of the test product versus 12 units of the reference product. The biostudy lots should be used for those product strengths tested *in vivo*. Because no official USP dissolution method is currently available for Buspirone Hydrochloride tablets, the FDA dissolution method should be followed. The following method and tolerances are currently recommended for this product:

Apparatus:	USP XXII apparatus II (Paddle)
RPM:	50 RPM
Medium:	0.01N HCl at 37 °C
Volume:	500 mL
Sampling Times:	10, 20, 30 and 45 minutes
Tolerance (Q):	NLT 80% in 30 minutes
Analytical:	As per USP XXII, if available, or

other validated method

The percent of label claim dissolved at each specified testing interval should be reported for each individual dosage unit. The mean percent dissolved, the range (highest, lowest) of dissolution, and the coefficient of variation (relative standard deviation) should be reported.

B. Content Uniformity Test

Content uniformity testing on the test product lots should be performed as described in USP XXII.

IV. WAIVER REQUIREMENTS

Waiver of *in vivo* bioequivalence study requirements for the 5 mg tablet of the generic product may be granted per 21 CFR 320.22(d)(2) provided both of the following conditions are met:

- A. The 5 mg tablet is proportionally similar in both active and inactive ingredients to the 10 mg tablet that has demonstrated bioequivalence to the listed reference (10 mg) product *in vivo*.
- B. The 5 mg strength of the generic product meets the specified dissolution testing requirement.

V. REFERENCES

1. Goa KL, Ward A. Buspirone: A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. *Drugs* 1986;32:114-29.
2. Taylor DP. Buspirone: a new approach to the treatment of anxiety. *FASEB* 1988;2:2445-52.
3. Murasaki M, Miura S, Ishigooka J, Ishil Y, Takahashi A, Fukuyama Y. Phase I study of a new antianxiety drug, buspirone. *Prog Neuro-Psychopharmacol Biol Psychiat* 1989;13:137-44.
4. Schuckit MA. Clinical studies of buspirone. *Psychopathology* 1984;17(suppl.3):61-8.

5. Physician's Desk Reference. 47th ed., Oradell, N.J., Medical Economics Company, 1993:1454-6.
6. Riblet LA, Eison AS, Eison MS, Taylor DP, Temple DL, VanderMaelen CP. Neuropharmacology of buspirone. Psychopathology 1984;17(suppl.3):69-78.
7. Riblet LA, Taylor DP, Eison MS, Stanton HC. Pharmacology and neurochemistry of buspirone. J Clin Psychiatry 1982;43:11-7.
8. Peroutka SJ. Selective interaction of novel anxiolytics with 5-hydroxytryptamine 1_A receptors. Biol Psychiatry 1985;20:971-9.
9. Jann MW. Buspirone: an update on a unique anxiolytic agent. Pharmacotherapy 1988;8:100-16.
10. Gammans RE, Mayol RF, Labudde JA. Metabolism and disposition of buspirone. Am J Med 1986;80:41-51.
11. Jajoo HK, Mayol RF, Labudde JA, Blair IA. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 1989;17:634-40.
12. Goldberg HL. Buspirone Hydrochloride: a unique new anxiolytic agent. Pharmacotherapy 1984;4:315-21.
13. Gammans RE, Westrick ML, Shea JP, Mayol RF, LaBudde JA. Pharmacokinetics of buspirone in elderly subjects. J Clin Pharmacol 1989;29:72-8.
14. Bullen WW, Bivens DL, Gammans RE, LaBudde JA. The binding of buspirone to human plasma proteins. Fed Proc 1985;44:1123
15. Kastenholz KV, Crismon ML. Buspirone, a novel nonbenzodiazepine anxiolytic. Clin Pharmacy 1984;3:600-607.
16. Gammans RE, Mayol RF, Mackenthun AV, Sokya LF. The relationship between buspirone bioavailability and dose in healthy subjects. Biopharmaceutics and Drug Dispos 1985;6:139-145.1.
17. Toothaker RD, Welling PG. The effect of food on drug bioavailability. Annu Rev Pharmacol Toxicol 1980;20:173-99.

18. Mayol RF, Gammans RE, Mackenthun AV, Soyka LF. The effect of food on the bioavailability of buspirone HCl. Clin Res 1983;31:631A.

Prepared by: _____ Date: _____
Sikta Pradhan, Ph.D.
Review Branch I
Division of Bioequivalence

Concur: _____ Date: _____
Shrikant V. Dighe, Ph.D.
Director,
Division of Bioequivalence
Office of Generic Drugs

Concur: _____ Date: _____
Roger L. Williams, M.D.
Director,
Office of Generic Drugs
Center for Drug Development Research